Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McGill University

$135,000.00

Modulation of The Serotonin System as a Novel Therapeutic Strategy in of Autism Spectrum Disorder

FY 2020-21

Summary
Autism spectrum disorder (ASD) is characterized by impairments in social behavior and emotional processing. To date, no therapies exist that specifically target ASD. ASD patients have altered activity in brain areas implicated in social behaviour, and emotions. Genetic animal models of human disease can help understand disease onset and progression, and whether new therapies might be effective in humans. Several studies suggest that the neurotransmitter serotonin, and in particular the serotonin 2A receptor, could be a potential target for novel ASD treatments. A preliminary study in our lab discovered that low doses of the 5-HT2A agonist Lysergic Acid Diethylamide (LSD) induce prosocial effects in mice. The main goal of the current study is to assess whether this treatment improves behaviour in two mouse models that display deficits similar to those in human ASD. Behavioral experiments will be employed to assess the sociability and anxiety levels of the ASD models at baseline. Subsequently, low-doses of LSD will be administered for 7 days and the behavioral experiments will be repeated. Next, the activity in several brain regions involved with ASD will be assessed in these models by recording the activity of individual neurons. Following the assessment of differences in brain activity at baseline, low doses of LSD will be administered for 7 days and the neuronal activity will be assessed again to determine whether this treatment normalized any neuronal dysfunctions. In the last part of the study, optogenetics will be used, which employs the activation of specific neurons by shining a laser light through an optical fiber. With this technique we will modulate the activity of selected brain areas to determine if this restores sociability. This is the first study which investigates if the psychedelic LSD, given at low doses, holds therapeutic value in treating a mouse model of ASD, which could provide the basis for translating this treatment in humans.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
440589
Name
Inserra Antonio
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Modulation of The Serotonin System as a Novel Therapeutic Strategy in of Autism Spectrum Disorder
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Autism Spectrum Disorder; Behavioural Pharmacology; Electrophysiology; Lysergic Acid Diethylamide; Molecular Pharmacology; Prefrontal Cortex; Serotonin; Serotonin 2a Receptor Agonism; Thalamus; Translational Study
Abstract
Autism spectrum disorder (ASD) is characterized by impairments in social behavior and emotional processing. To date, no therapies exist that specifically target ASD. ASD patients have altered activity in brain areas implicated in social behaviour, and emotions. Genetic animal models of human disease can help understand disease onset and progression, and whether new therapies might be effective in humans. Several studies suggest that the neurotransmitter serotonin, and in particular the serotonin 2A receptor, could be a potential target for novel ASD treatments. A preliminary study in our lab discovered that low doses of the 5-HT2A agonist Lysergic Acid Diethylamide (LSD) induce prosocial effects in mice. The main goal of the current study is to assess whether this treatment improves behaviour in two mouse models that display deficits similar to those in human ASD. Behavioral experiments will be employed to assess the sociability and anxiety levels of the ASD models at baseline. Subsequently, low-doses of LSD will be administered for 7 days and the behavioral experiments will be repeated. Next, the activity in several brain regions involved with ASD will be assessed in these models by recording the activity of individual neurons. Following the assessment of differences in brain activity at baseline, low doses of LSD will be administered for 7 days and the neuronal activity will be assessed again to determine whether this treatment normalized any neuronal dysfunctions. In the last part of the study, optogenetics will be used, which employs the activation of specific neurons by shining a laser light through an optical fiber. With this technique we will modulate the activity of selected brain areas to determine if this restores sociability. This is the first study which investigates if the psychedelic LSD, given at low doses, holds therapeutic value in treating a mouse model of ASD, which could provide the basis for translating this treatment in humans.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Inserra, Antonio
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~